Chinese instructions for rubidine (Zepzelca)

Rupitidine (Zepzelca) is a chemotherapy drug used for the second-line treatment of recurrent small cell lung cancer. As the first marine-derived RNA polymerase inhibitor, rupitidine (Zepzelca) brings therapeutic hope to patients with certain tumors.

Indications of rupitidine (Zepzelca)

Rubitidine (Zepzelca) is a targeted therapy drug for the treatment of metastatic small cell lung cancer (SCLC). It is suitable for adult patients whose disease has progressed during or after platinum-containing chemotherapy.

Side effects of rupitidine (Zepzelca)

1. Allergic reaction

If you have an allergic reaction (urticaria, difficulty breathing, swelling of the face/lips/tongue/throat), please seek medical attention immediately.

2. Serious side effects

If the following side effects occur, please contact your doctor immediately:

Skin: Abnormal bleeding or bruising, purple-red spots under the skin.

Anemia: paleness, fatigue, dizziness, shortness of breath, cold hands and feet.

Leucopenia: fever, oral ulcers, skin ulcers, sore throat, cough, difficulty breathing.

Signs of sepsis: confusion, chills, high fever, drowsiness, fast heart rate, shortness of breath, extreme discomfort.

Abnormal liver function: loss of appetite, right upper quadrant pain, fatigue, itching, dark urine, clay-colored stools, jaundice.

3. Common side effects

Reduced blood cell count, cough, difficulty breathing, nausea, vomiting, loss of appetite, increased thirst or urine output, diarrhea or constipation, muscle/joint pain, fatigue, abnormal blood tests.

Recommended articles:

Instructions before taking rupitidine (Zepzelca)

1. You need to inform the doctor of your medical history

Patients with liver disease or kidney disease need to inform the doctor before taking medication.

2. Fertility-related precautions

Female: It is necessary to confirm that you are not pregnant before taking the medicine; you need to take effective contraceptive measures during treatment and within 6 months after the last dose.

Male: If the partner is of childbearing potential, contraception is required during treatment and within 4 months after the last dose.

Pregnancy: Disabled. If you become pregnant while taking this medicine, please inform your doctor immediately.

Lactation period: Avoid breastfeeding during treatment and within 2 weeks after the last dose.

Rubitidine (Zepzelca) usage and dosage

1. Administration method

(1) Intravenous infusion, at least 60 minutes each time, once every 21 days.

(2) Liver function and blood cell count (ANC ≥ 1500/mm³, platelets ≥ 100,000/mm³) need to be tested before medication.

(3) Antiemetic drugs (such as dexamethasone 8mg intravenously or equivalent drugs) can be used in advance.

2. Standard adult dose

Each intravenous infusion of 3.2 mg/m², once every 21 days, until disease progression or intolerable toxicity occurs.

3. Missed dose or overdose

Missed dose: Contact your doctor immediately to adjust the follow-up plan.

Overdose: Overdose is rare when administered under medical supervision.

Recommended article:

Contraindications for the use of Rubitidine (Zepzelca)

Avoid grapefruit or products (may increase the risk of side effects).

Rupitidine (Zepzelca) Drug Interactions

Strong inhibitors/inducers of CYP3A may affect the efficacy of the drug, so combined use should be avoided. Tell your doctor about all prescription, over-the-counter, vitamins, and herbal medicines.

Note: If you want to know more details, please check the original instructions of the drug. Please follow the doctor's instructions for specific medication.